Suppr超能文献

肝硬化中的门静脉血栓形成

Portal vein thrombosis in cirrhosis.

作者信息

Raja Kaiser, Jacob Mathew, Asthana Sonal

机构信息

Department of Hepatology, Hepatobiliary Surgery & Multiorgan Transplantation, Global Integrated Liver Care Program, BGS Global Hospitals, Bangalore, India.

出版信息

J Clin Exp Hepatol. 2014 Dec;4(4):320-31. doi: 10.1016/j.jceh.2013.12.003. Epub 2013 Dec 31.

Abstract

Portal vein thrombosis (PVT) is being increasingly recognized in patients with advanced cirrhosis and in those undergoing liver transplantation. Reduced flow in the portal vein is probably responsible for clotting in the spleno-porto-mesenteric venous system. There is also increasing evidence that hypercoagulability occurs in advanced liver disease and contributes to the risk of PVT. Ultrasound based studies have reported a prevalence of PVT in 10-25% of cirrhotic patients without hepatocellular carcinoma. Partial thrombosis of the portal vein is more common and may not have pathophysiological consequences. However, there is high risk of progression of partial PVT to complete PVT that may cause exacerbation of portal hypertension and progression of liver insufficiency. It is thus, essential to accurately diagnose and stage PVT in patients waiting for transplantation and consider anticoagulation therapy. Therapy with low molecular weight heparin and vitamin K antagonists has been shown to achieve complete and partial recanalization in 33-45% and 15-35% of cases respectively. There are however, no guidelines to help determine the dose and therapeutic efficacy of anticoagulation in patients with cirrhosis. Anticoagulation therapy related bleeding is the most feared complication but it appears that the risk of variceal bleeding is more likely to be dependent on portal pressure rather than solely related to coagulation status. TIPS has also been reported to restore patency of the portal vein. Patients with complete PVT currently do not form an absolute contraindication for liver transplantation. Thrombectomy or thromboendovenectomy is possible in more than 75% of patients followed by anatomical end-to-end portal anastomosis. When patency of the portal vein and/or superior mesenteric vein is not achieved, only non-anatomical techniques (reno-portal anastomosis or cavo-portal hemitransposition) can be performed. These techniques, which do not fully reverse portal hypertension, are associated with higher morbidity and mortality risks in the short term.

摘要

门静脉血栓形成(PVT)在晚期肝硬化患者和接受肝移植的患者中越来越受到关注。门静脉血流减少可能是脾-门静脉-肠系膜静脉系统血栓形成的原因。越来越多的证据表明,晚期肝病患者存在高凝状态,这增加了PVT的风险。基于超声的研究报告显示,在无肝细胞癌的肝硬化患者中,PVT的发生率为10%-25%。门静脉部分血栓形成更为常见,可能不会产生病理生理后果。然而,部分PVT进展为完全PVT的风险很高,这可能会导致门静脉高压加剧和肝功能不全进展。因此,准确诊断并对等待移植的患者进行PVT分期,并考虑抗凝治疗至关重要。低分子量肝素和维生素K拮抗剂治疗分别在33%-45%和15%-35%的病例中实现了完全和部分再通。然而,目前尚无指导原则来帮助确定肝硬化患者抗凝治疗的剂量和疗效。抗凝治疗相关出血是最令人担忧的并发症,但似乎静脉曲张出血的风险更可能取决于门静脉压力,而不仅仅与凝血状态有关。也有报道称经颈静脉肝内门体分流术(TIPS)可恢复门静脉通畅。目前,完全PVT患者并非肝移植的绝对禁忌证。超过75%的患者可行血栓切除术或血栓内膜切除术,随后进行解剖性端端门静脉吻合术。当无法实现门静脉和/或肠系膜上静脉通畅时,只能采用非解剖技术(肾门静脉吻合术或腔门静脉半转位术)。这些技术不能完全逆转门静脉高压,在短期内与较高的发病率和死亡率风险相关。

相似文献

1
Portal vein thrombosis in cirrhosis.
J Clin Exp Hepatol. 2014 Dec;4(4):320-31. doi: 10.1016/j.jceh.2013.12.003. Epub 2013 Dec 31.
2
Portal vein thrombosis.
J Clin Exp Hepatol. 2015 Mar;5(1):22-40. doi: 10.1016/j.jceh.2014.12.008. Epub 2015 Jan 6.
3
Portal vein thrombosis after partial splenic embolization in liver cirrhosis: efficacy of anticoagulation and long-term follow-up.
J Vasc Interv Radiol. 2013 Dec;24(12):1808-16. doi: 10.1016/j.jvir.2013.08.018. Epub 2013 Oct 4.
4
Portal vein thrombosis, cirrhosis, and liver transplantation.
J Hepatol. 2012 Jul;57(1):203-12. doi: 10.1016/j.jhep.2011.12.034. Epub 2012 Mar 21.
5
Portal Vein Thrombosis in Cirrhosis.
J Clin Exp Hepatol. 2022 May-Jun;12(3):965-979. doi: 10.1016/j.jceh.2021.11.003. Epub 2021 Nov 22.
8
Nontumoral Portal Vein Thrombosis: A Challenging Consequence of Liver Cirrhosis.
J Clin Transl Hepatol. 2020 Dec 28;8(4):432-444. doi: 10.14218/JCTH.2020.00067. Epub 2020 Nov 11.
9
Portal vein thrombosis: yes or no on anticoagulation therapy.
Curr Opin Organ Transplant. 2018 Apr;23(2):250-256. doi: 10.1097/MOT.0000000000000506.

引用本文的文献

1
The Molecular Mechanisms of Portal Vein Thrombosis in Hepatocellular Carcinoma.
Cancers (Basel). 2024 Sep 24;16(19):3247. doi: 10.3390/cancers16193247.
2
Muscle-Invasive Bladder Cancer in Patients with Liver Cirrhosis: A Review of Pertinent Considerations.
Bladder Cancer. 2021 Aug 31;7(3):261-278. doi: 10.3233/BLC-211536. eCollection 2021.
3
Portal Vein Thrombosis in Patients With Cirrhosis of the Liver: Prevalence and Risk Factors.
Cureus. 2023 Dec 7;15(12):e50134. doi: 10.7759/cureus.50134. eCollection 2023 Dec.
8
Endovascular transsplenic recanalization with angioplasty and stenting of an occluded main portal vein in an adult liver transplant recipient.
Radiol Case Rep. 2020 Mar 21;15(5):615-623. doi: 10.1016/j.radcr.2020.02.026. eCollection 2020 May.
10
The risk factors of portal vein thrombosis in patients with liver cirrhosis.
Exp Ther Med. 2019 Apr;17(4):3189-3194. doi: 10.3892/etm.2019.7300. Epub 2019 Feb 22.

本文引用的文献

1
Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats.
J Hepatol. 2013 Aug;59(2):358-66. doi: 10.1016/j.jhep.2013.03.027. Epub 2013 Mar 30.
2
De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes.
Am J Gastroenterol. 2013 Apr;108(4):568-74. doi: 10.1038/ajg.2012.452. Epub 2013 Feb 5.
3
Management of nonneoplastic portal vein thrombosis in the setting of liver transplantation: a systematic review.
Transplantation. 2012 Dec 15;94(11):1145-53. doi: 10.1097/TP.0b013e31826e8e53.
4
Management of anticoagulation for portal vein thrombosis in individuals with cirrhosis: a systematic review.
Int J Hepatol. 2012;2012:672986. doi: 10.1155/2012/672986. Epub 2012 Jun 20.
5
Portal vein thrombosis, cirrhosis, and liver transplantation.
J Hepatol. 2012 Jul;57(1):203-12. doi: 10.1016/j.jhep.2011.12.034. Epub 2012 Mar 21.
7
Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis.
Clin Gastroenterol Hepatol. 2012 Jul;10(7):776-83. doi: 10.1016/j.cgh.2012.01.012. Epub 2012 Jan 28.
9
The coagulopathy of chronic liver disease.
N Engl J Med. 2011 Jul 14;365(2):147-56. doi: 10.1056/NEJMra1011170.
10
Hypercoagulability in cirrhosis: causes and consequences.
J Thromb Haemost. 2011 Sep;9(9):1713-23. doi: 10.1111/j.1538-7836.2011.04429.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验